Research and Markets has announced the addition of the "CNS Drug Discoveries:
Multiple Sclerosis Chapter" report to their offering.
This chapter of
CNS Drug Discoveries focuses on the multiple sclerosis market.
With the
launch of up to 12 new disease-modifying agents, three vaccines and one novel
drug designed to treat the symptoms of multiple sclerosis (MS) and improve
quality of life, the MS market is in an exciting phase of evolution.
The
MS market is estimated to be worth almost US$8 billion in 2008, with a growth
rate of 10.6% year-on-year. It is the fifth largest segment of the CNS markets
considered in this report and has attracted considerable R&D investment from
the big pharmaceutical companies, biotechnology companies and specialty pharma.
Over the next six years a number of oral agents are expected to be
launched that could drastically change the way in which MS patients are treated.
These include: Novartis' fingolimod, Teva's laquinimod, Merck KGaA's Mylinax
(cladribine), sanofi-aventis' teriflunomide and Biogen Idec's BG-12 in Phase III
development, and GSK/Mitsubishi Tanabe Pharma's firategrast, MediciNova's
ibudilast and Biogen/UCB's CDP323 in Phase II development.
Three
companies have taken on the ambitious task of developing vaccines to treat MS
and each has adopted a unique approach to addressing the underlying causes of
the disease. Orchestra Therapeutic's NeuroVax targets three proteins expressed
on T-cell receptors whilst Opexa Therapeutics' Tovaxin uses attenuated
autologous cells to stimulant an immune response. Bayhill Therapeutics is
developing BHT-3009, a tolerising DNA vaccine. All vaccines are in Phase II
development and could reach market by 2012.
Key MS questions
answered: - What is the estimated global population for MS in 2014
and what % will be diagnosed and treated?
- Which off-patent MS treatments
are resistant to generic competition?
- Will Biogen Idec, Teva and Merck
KGaA be able to defend their leading positions in 5 years time?
- There are
7 late-phase pipeline products which target the underlying cause of MS - what
are their strengths and weaknesses?
Key Topics Covered: -
Executive Summary
- The Facts
- Patient Statistics
- Patient Model
-
Drug Growth Drivers
- Drug Growth Risks/Dampeners
- The Ms Market
-
Current Ms Treatments
- Global Sales Forecasts Of Current Treatments
2007a-2014e
- Analysis Of Phase Iii Drugs
- Global Sales Forecasts Of
Phase III Ms Drugs 2009e-2014e
- Analysis Of Phase Ii Drugs
- Global Sales
Forecasts Of Phase Ii Ms Drugs 2011e - 2014e
- Competitor Ratio Analysis
-
Competitor Ratio Analysis - Products
- Competitor Ratio Analysis -
Companies
- Winners & Losers
- Discontinuation Of Drugs
- MS
Glossary
- MS References
- Acronymns
Key Products Analysed and
Forecast:- BG-12 - Biogen Idec
-
Campath -
Bayer
- Fingolimod - Novartis
- Lacquinimod - Teva
- MBP 8298 -
BioMS/Lilly
- Mylinax - Merck KGaA
- Teriflunomide - sanofi-aventis
-
Neurelan - Elan/Acorda
For more information visit
here.Source: Espicom Business
Intelligence Ltd
Research and Markets
